1. Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
- Author
-
Guglietti B, Sivasankar S, Mustafa S, Corrigan F, and Collins-Praino LE
- Subjects
- Alzheimer Disease drug therapy, Alzheimer Disease enzymology, Alzheimer Disease physiopathology, Amyloid beta-Peptides metabolism, Benzamides pharmacology, Benzamides therapeutic use, Central Nervous System enzymology, Dasatinib pharmacology, Dasatinib therapeutic use, Humans, Molecular Targeted Therapy, Multiple Sclerosis drug therapy, Multiple Sclerosis enzymology, Myelin Sheath physiology, Nerve Tissue Proteins drug effects, Neurodegenerative Diseases drug therapy, Neurodegenerative Diseases physiopathology, Oligodendroglia metabolism, Parkinson Disease drug therapy, Parkinson Disease enzymology, Parkinson Disease physiopathology, Piperidines pharmacology, Piperidines therapeutic use, PrPC Proteins metabolism, Proto-Oncogene Proteins c-fyn antagonists & inhibitors, Proto-Oncogene Proteins c-fyn drug effects, Pyridines pharmacology, Pyridines therapeutic use, Receptors, N-Methyl-D-Aspartate metabolism, T-Cell Antigen Receptor Specificity, T-Lymphocyte Subsets enzymology, T-Lymphocyte Subsets immunology, Thiazoles pharmacology, Thiazoles therapeutic use, tau Proteins metabolism, Nerve Tissue Proteins physiology, Neurodegenerative Diseases enzymology, Proto-Oncogene Proteins c-fyn physiology
- Abstract
Fyn is a non-receptor tyrosine kinase belonging to the Src family of kinases (SFKs) which has been implicated in several integral functions throughout the central nervous system (CNS), including myelination and synaptic transmission. More recently, Fyn dysfunction has been associated with pathological processes observed in neurodegenerative diseases, such as multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD). Neurodegenerative diseases are amongst the leading cause of death and disability worldwide and, due to the ageing population, prevalence is predicted to rise in the coming years. Symptoms across neurodegenerative diseases are both debilitating and degenerative in nature and, concerningly, there are currently no disease-modifying therapies to prevent their progression. As such, it is important to identify potential new therapeutic targets. This review will outline the role of Fyn in normal/homeostatic processes, as well as degenerative/pathological mechanisms associated with neurodegenerative diseases, such as demyelination, pathological protein aggregation, neuroinflammation and cognitive dysfunction., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF